Lycia Therapeutics is banking on a $227.8 million IPO as the biotech seeks to finance its pipeline of protein degraders for ...
Oracle kicked off the year by launching its Oracle Life Sciences AI Data Platform, which it touted as using generative AI, ...
Ambrose Healthcare has bought AM-Pharma for up to 161 million euros ($181 million), inking a cut-price deal for the Dutch ...
Rapport's phase 2 bipolar win strikes chord with analysts despite falling short of original ambition
Rapport Therapeutics’ phase 2 bipolar mania study has hit its primary endpoint, furthering the biotech’s efforts to make RAP-219 a multi-indication blockbuster. However, the effect size fell short of ...
Medtech M&A reached its highest level in more than a decade, EY found, with a total disclosed deal value of roughly $130 ...
Nano24’s inhaled exosome therapy reduced respiratory failure in patients with acute respiratory distress syndrome (ARDS), ...
Amid the Chinese biopharma licensing boom, Hengrui Pharmaceuticals stands out from the crowd. | Amid the Chinese biotech ...
Last Friday, Frazier Life Sciences hit the Nasdaq with its second biotech-focused SPAC. TCGX is already on the hunt for ...
AbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial. Skyrizi is a ...
Germany’s Merck KGaA has picked up Silence Therapeutics to the tune of $1.3 billion in the wake of the British biotech’s mid-stage success for its challenger to Takeda’s Mimrylo. The all-cash deal ...
Nouscom has reeled in 120 million euros ($135 million) in series D funds to take a cancer-preventing vaccine through a ...
Disc’s phase 3 trial provides a clearer link between the biomarker, whole-blood metal-free protoporphyrin IX (PPIX), and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results